Geriatrics, Health Services for the Aged, Residence for Dependent Elderly
Conditions
Keywords
Multidisciplinary review of drug prescriptions, Adverse drug events geriatric risk score, Residence for dependent elderly
Brief summary
The main objective of the study is to show that the multidisciplinary review of drug prescriptions changes the adverse drug event (ADE) geriatric risk score (according to Trivalle and Ducimetière 2013) for patients living in the Nîmes University Hospital Residence for Dependent Elderly.
Detailed description
The secondary objectives of this study are to assess and compare the following criteria before and after multidisciplinary review of drug prescriptions for patients in the Nîmes University Hospital Residence for Dependent Elderly: A. the number of patients with at least one potentially inappropriate drug prescribed B. the number of hospitalizations C. death rate D. the number of falls per patient and the rate of fallers E. qualitative criteria describing the drug review F. associated care costs
Interventions
OTHERBefore-after study
The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase. The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score. The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence. During the second observational phase, the same data as in the first observational phase will be collected a second time.
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient (or his/her legal representative) must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 6 months of follow-up * The patient has resided at the Nîmes University Hospital Residence for Dependent Elderly for at least the past 6 months
Exclusion criteria
* The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection * The patient (or his/her legal representative) refuses to sign the consent * It is impossible to correctly inform the patient (or his/her legal representative) * The patient has resided at the Nîmes University Hospital Residence for Dependent Elderly for less than 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Drug Events Geriatric Risk Score | change from Baseline to 6 months | according to Trivalle and Ducimetière 2013 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of hospitalizations in the public sector (higher level care) | first observational phase (month -6 to day 0) | — |
| Days of hospitalization in the public sector (higher level care) | first observational phase (month -6 to day 0) | — |
| Mortality | first observational phase (month -6 to day 0) | — |
| The number of falls per patient | first observational phase (month -6 to day 0) | — |
| The percentage of patients who fell | first observational phase (month -6 to day 0) | — |
| The number of patients taking at least 1 potentially inappropriate drug according to Laroche criteria | During the proactive phase. Day 0. | Laroche et al 2007. |
| The type of errors detected during drug review | during the proactive phase (day 0) | Contra-indication, dosing, route, etc |
| The type of modification suggested during drug review | during the proactive phase (day 0) | discontinuation, addition, substitution... |
| The acceptation rate for modifications suggested during drug review | during the proactive phase (day 0) | — |
| Associated care costs (€) | first observational phase (month -6 to day 0) | — |
| The Anatomical Therapeutic Chemical classification for each revised drug | during the proactive phase (day 0) | — |
Countries
France
Outcome results
None listed